id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2420550,7ec9c022-a5a5-48ea-8f5b-be35876d8cd7,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2020,first_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2020-04-01T12:27:56.353000-04:00
2420586,58c7edb3-ff7e-43d2-bf66-477a55476564,Q1,"4C COMMUNICATIONS, INC.",323717,HEALTHCARE LEADERSHIP COUNCIL,2020,first_quarter,PHA,Discussion on pharmaceutical drug pricing; cost of pharmaceutical drugs in the Medicare Part D program,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-01T14:45:17.390000-04:00
2421630,bb244e5d-47db-45c0-a5ac-4d67906469a2,Q1,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2020,first_quarter,PHA,"Discussed potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2020-04-07T11:12:22.827000-04:00
2421744,8c2c4492-5eb4-481f-b44b-302955b119f4,Q1,HOLLAND & KNIGHT LLP,18466,"TEVA PHARMACEUTICALS USA, INC.",2020,first_quarter,PHA,"Drug pricing; Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748).","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-07T14:05:58.950000-04:00
2421824,df03fd0f-2edd-4fb2-b4fc-9941d9bfbe51,Q1,JOHNSON MATTHEY INC.,401104441,JOHNSON MATTHEY INC.,2020,first_quarter,PHA,"H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market.

H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents.

H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents.

H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents.

S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.","HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2020-04-07T14:47:47.110000-04:00
2421873,eb123b0f-309f-4b74-9b1d-8f6e932902d4,Q1,PENN AVENUE PARTNERS,400918672,"ALKERMES, INC.",2020,first_quarter,PHA,"Regulatory and legislative issues impacting Alkermes.
S.3312: Crisis Stabilization and Community Reentry Act of 2020.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-07T16:09:25.093000-04:00
2421978,a7d506d3-b50b-443f-90e1-33cdbbe879aa,Q1,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2020,first_quarter,PHA,"H.R. 748 - CARES Act - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.

H.R. 6201 - Families First Coronavirus Response Act -  Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Issues related to supporting programs and institutions supporting during the current pandemic. 

HHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-08T10:20:04.430000-04:00
2421988,382b6856-f8f1-4730-9076-77094dfb061b,Q1,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2020,first_quarter,PHA,"H.R. 748 - CARES Act - Issues related to supporting the national work fighting COVID-19 and ensuring that antibiotics are available during the COVID-19 crisis and beyond and OTC monograph reform is address to enhance patient safety.

H.R. 6201 - Families First Coronavirus Response Act -  Issues related to ensuring that the federal government is best supporting the public good with a focus on ensuring there is a strong antibiotics pipeline to fight secondary infections and over the counter medications are safe and secure.

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Issues related to supporting programs and institutions supporting during the current pandemic. 


S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. 

H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. 

H.R. 3443 - The OTC Monograph Safety Innovation and Reform Act of 2019 - Support for policies that enable OTC monograph reform. 

Issues related to creating a listing mechanism for dietary supplements. 

Issues related to the implementation on the SUPPORT Act (P.L. 115-271)  



S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. 

H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-08T10:40:15.957000-04:00
2422418,89923d8a-7e0c-448b-8c3d-f51885cdb790,Q1,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2020,first_quarter,PHA,"HR 4392- To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines.
H.R. 3. Lower Prescription Drug Costs Now Act - legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.","HOUSE OF REPRESENTATIVES,SENATE",,252275,0,0,2020-04-09T12:13:57.773000-04:00
2422478,d3907e17-4ce0-4503-aaf5-847e59ca0439,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2020,first_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value. 
Prescription drug importation.
Issues related to regulation of prescription opioid medication.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-09T14:31:17.347000-04:00
2422507,066de8e3-4488-4bed-b338-0abddb6a0b73,Q1,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2020,first_quarter,PHA,"Issues related to pharmaceutical market value.
H.R.965/S.340: CREATES Act of 2019.
Proposed Notice of Benefit and Payment Parameters (NBPP) Rule for 2021.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-09T14:43:38.940000-04:00
2422628,f3a255db-9b64-4cae-84fa-001ef767403b,Q1,HOLLAND & KNIGHT LLP,18466,VIATRIS INC,2020,first_quarter,PHA,"Drug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, the consumer price index, generic drugs.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-09T16:33:26.343000-04:00
2422810,daa50085-ced8-4173-b234-80315e6b906a,Q1,ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP),400637926,ACCREDITATION COMMISSION FOR HEALTH CARE,2020,first_quarter,PHA,Issues related to compounding pharmacy practice.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-04-10T11:15:02.713000-04:00
2422812,34dfa5a4-8329-42c2-9501-e8c6011a13d9,Q1,ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP),400637926,PANTHERX,2020,first_quarter,PHA,Issues related to the specialty pharmacy practice.,,,,0,0,2020-04-10T11:16:04.127000-04:00
2422859,3104fc41-0609-4fc0-9591-7683a810be39,Q1,TAUZIN STRATEGIC NETWORKS,400786367,CAPTURERX,2020,first_quarter,PHA,Issues related to the 340b program,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-10T11:38:02.470000-04:00
2423209,ea4f3dc9-683e-4b20-8ea9-af4cdb082292,Q1,ACG ADVOCACY,2057,WALGREEN CO.,2020,first_quarter,PHA,"Drug Pricing Policy Issues.
Data privacy and DIR fee reform.
Public Health Crisis.
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2020-04-10T17:26:56.807000-04:00
2423416,6255e1be-ca8b-4b8d-9333-051088e2d213,Q1,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2020,first_quarter,PHA,Monitor Data and Science Policy.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-11T14:13:24.893000-04:00
2423528,ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8,Q1,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2020,first_quarter,PHA,"H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.

H.R. 6201 - Families First Coronavirus Response Act  - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 748 - The CARES Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. 

H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.

S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. 

Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-12T14:44:52.997000-04:00
2423559,8ac2a863-9d50-4489-b956-70359eccc345,Q1,ACG ADVOCACY,2057,GENENTECH INC,2020,first_quarter,PHA,"Drug Pricing Issues.
Public Health Crisis.
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office",40000,,0,0,2020-04-13T08:44:23.677000-04:00
2423609,bbd4c069-8ec6-4865-994d-3398447667e1,Q1,THE KUTLER GROUP,401103966,PRIME THERAPEUTICS,2020,first_quarter,PHA,"drug pricing issues
monitor Covid 19 legislation","HOUSE OF REPRESENTATIVES,SENATE",24000,,0,0,2020-04-13T10:11:03.830000-04:00
2423829,2cccd489-e899-4c6c-8bc8-b8e966566bbf,Q1,SOUTHERN ILLINOIS UNIVERSITY,6564,SOUTHERN ILLINOIS UNIVERSITY,2020,first_quarter,PHA,Met with Congressman LaHood on Feb 20 at the Simmons Cancer Institute to talk about 340B pricing and other cancer-related issues including Simmons outreach to the African American community to discuss cancer testing and prevention.,HOUSE OF REPRESENTATIVES,,11250,0,0,2020-04-13T11:56:23.847000-04:00
2424116,f076db48-cca4-4510-9322-7c747f9c0d32,Q1,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2020,first_quarter,PHA,"Issues related to prescription drug value.

S.2543: Prescription Drug Pricing Reduction Act of 2019.

H.R.3: Lower Drug Costs Now Act of 2019.

H.R.19/S.3129: Lower Costs, More Cures Act of 2019.

Biosimilars.

Importation of prescription drugs.

340B issues.

FDA regulatory issues, including the International Pricing Index.

Issues related to the COVID-19 pandemic.

H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.

H.R.6201: Families First Coronavirus Response Act.

H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office",60000,,0,0,2020-04-13T14:54:20.970000-04:00
2424157,98634ee8-1d1d-482c-8299-61abcb39dc61,Q1,"MARSHALL & POPP, LLC",401105121,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2020,first_quarter,PHA,"Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3/: Lower Drug Costs Now Act of 2019, and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.

Biosimilars. 

Importation of prescription drugs. 

340B issues. 

FDA regulatory issues, including the International Pricing Index.

Issues related to the COVID-19 pandemic.

H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.

H.R.6201: Families First Coronavirus Response Act.

H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office",50000,,0,0,2020-04-13T15:13:31.190000-04:00
2424161,ed1f9520-700a-4328-ac42-dba0018eabb1,Q1,"MARSHALL & POPP, LLC",401105121,"SANOFI U.S. SERVICES, INC.",2020,first_quarter,PHA,"Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.

Biosimilars.

Importation of prescription drugs.

340B issues.

FDA regulatory issues, including the International Pricing Index.

Issues related to the COVID-19 pandemic.

H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.

H.R.6201: Families First Coronavirus Response Act.

H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office",60000,,0,0,2020-04-13T15:17:32.377000-04:00
2424185,5e45c6d5-df55-4871-afcd-fbbaafe8329e,Q1,WAXMAN STRATEGIES,401103693,340B HEALTH,2020,first_quarter,PHA,Issues affecting the 340B drug pricing program; Appropriations for 340B program.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-13T15:26:38.543000-04:00
2424189,5d4184c5-24a6-4b76-a5ee-9de9b46a1953,Q1,FARRAGUT PARTNERS LLP,401103938,COMMUNITY ONCOLOGY ALLIANCE,2020,first_quarter,PHA,Issues related to pharmacy benefit managers.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-04-13T15:28:39.783000-04:00
2424483,d7392111-2c6e-4984-a4f5-c9bd1ee9c2ef,Q1,"CONNECT 4 STRATEGIES, LLC",401103720,FCS FOUNDATION,2020,first_quarter,PHA,FDA processes,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-13T20:12:07.250000-04:00
2424616,b9fc3fa3-dcd3-42aa-aa64-04a0344b7a1d,Q1,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2020,first_quarter,PHA,Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to continuation of prescription drug access and testing during COVID crisis.,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2020-04-14T08:57:36.837000-04:00
2424950,43a8d74e-2b36-48d1-82cf-f52d9a5fe37c,Q1,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2020,first_quarter,PHA,Monitoring biotech legislation; prescription drug prices,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-04-14T12:30:12.947000-04:00
2424977,0363409a-77f0-44b3-9ede-8d7c117da13d,Q1,LUNGREN LOPINA LLC,401103314,AMPAC FINE CHEMICALS,2020,first_quarter,PHA,Fair treatment for US based pharmaceutical ingredients,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-04-14T12:58:22.030000-04:00
2424997,1bf177eb-2d39-491b-a6cc-c65f7b025ae1,Q1,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2020,first_quarter,PHA,"Issues related to ARCOS data and suspicious order record requirements and reporting (S.3070-Preventing Pill Mills Through Data Sharing Act, S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019); importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-14T13:21:29.807000-04:00
2425081,106afdfb-a7a5-47a5-869c-b1637e19a17a,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2020,first_quarter,PHA,"Drug coverage & reimbursement

no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay

H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 1895 - Lower Health Care Costs Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-14T14:12:52.797000-04:00
2425145,eca5250c-a816-4e72-a9b2-d878e6cf13bc,Q1,POLSINELLI PC,314911,"TEVA PHARMACEUTICALS USA, INC.",2020,first_quarter,PHA,"S. 2543, Prescription Drug Pricing Reduction Act
S. 1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act 
H.R. 6201, Families First Coronavirus Response Act
H.R. 748, CARES Act
Review of Administration drug pricing policies","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-04-14T14:49:19.267000-04:00
2425322,fd3dcc33-0efd-4a0a-93f1-e53de890c714,Q1,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2020,first_quarter,PHA,In-office Compounding,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",,,0,0,2020-04-14T16:15:14.947000-04:00
2425419,eb9afb29-08e4-4456-ba77-8d5e855f1908,Q1,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2020,first_quarter,PHA,"The Prescription Drug Pricing Reduction Act S. 2543-IPC supports.
Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale.
Support regulations that would eliminate pharmacy DIR.
IPC supports Pharmacists as providers under Medicare Part D
IPC supports Pharmacists as Imunnizers
First Families Coronavirus Response Act 2020. IPC supports
The Coronavirus Aid, Relief and Economic Security Act 2020. IPC supports","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,30000,0,0,2020-04-14T17:02:49.760000-04:00
2425448,8021ebd5-c0fc-4e12-a41c-6f5afb7ddbe7,Q1,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2020,first_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-14T17:24:00.940000-04:00
2425534,bb8b4a93-a8ea-47e2-be1f-940c78050da4,Q1,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2020,first_quarter,PHA,Prescription Drug User Fee,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2020-04-15T08:26:37.967000-04:00
2425536,0c67f07c-4d19-41bb-b777-9ca0abbea2b3,Q1,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2020,first_quarter,PHA,Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",45000,,0,0,2020-04-15T08:32:38.987000-04:00
2425537,441f1a37-d251-4646-b14c-3f54730e647c,Q1,"RUBICON ADVISORS, LLC",315091,CONSCIOUS DISCIPLINE,2020,first_quarter,PHA,Medicare,"HOUSE OF REPRESENTATIVES,SENATE",37500,,0,0,2020-04-15T08:38:39.793000-04:00
2425657,aa0f7ced-218a-4978-9f64-78d11b1ba7f2,Q1,NATIONAL RURAL HEALTH ASSOCATION,53048,NATIONAL RURAL HEALTH ASSOCATION,2020,first_quarter,PHA,The 340B Program and drug pricing,"Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE",,291971,0,0,2020-04-15T09:50:20.760000-04:00
2425851,5b4ee2bd-aece-4572-a935-83ac92fb71c2,Q1,"RUBICON ADVISORS, LLC",315091,"LANNETT COMPANY, INC",2020,first_quarter,PHA,"Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",20000,,0,0,2020-04-15T11:06:18.580000-04:00
2425928,7817b081-cb35-4d1d-a406-1dbfe9adeb32,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2020,first_quarter,PHA,"H.R. 1781 - Payment Commission Data Act of 2019
H.R. 938 - the BLOCKING Act of 2019
H.R. 1520 - the Purple Book Continuity Act of 2019
H.R. 1503 - the Orange Book Transparency Act of 2019
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R. 965 - the CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions For Patients Act of 2019 
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019


no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2020-04-15T11:34:48.310000-04:00
2426032,ea970a29-aeb1-4f9c-ae6f-ce71c0146235,Q1,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2020,first_quarter,PHA,"Educate Members on pharmacy contracting with pharmacy benefit managers
Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing
S 1895 Lower Healthcare Costs Act
HR 2296 Fair Accountability and Innovative Research Drug Pricing Act
HR 2376 Prescription Pricing for the People Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-15T12:10:25.597000-04:00
2426123,83aa9440-05dd-4527-b8f2-4a0db34318e9,Q1,"MEHLMAN CONSULTING, INC.",284950,"AARP, INC.",2020,first_quarter,PHA,"S.1895 - Lower Health Care Costs Act including issues relating to drug pricing 
Older Americans Reauthorization Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019.
House prescription drug price transparency legislation.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-15T12:24:52.653000-04:00
2426309,d3e22154-dd43-4eda-bfdc-5af0c29c41c5,Q1,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2020,first_quarter,PHA,GFI 256 FDA Compounding Guidance;,"Agriculture, Dept of (USDA),Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",320000,,0,0,2020-04-15T13:29:48.717000-04:00
2426333,4fed2622-8609-4194-98ba-ec63a3f7b19d,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2020,first_quarter,PHA,"Importation of prescription drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844)
Opioid Abuse - General issues related to opioid drug abuse (Implementation of Public Law 115-271)
Implementation of Public Law 113-54 (DSCSA)
Issues Related to ARCOS data and suspicious order record requirements & reporting
Block, Report, and Suspend Suspicious Shipments Act of 2019 (H.R. 3878)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-04-15T13:34:55.107000-04:00
2426926,91d55450-3818-4e66-accd-5fbb06de315a,Q1,"POLITICAL CAPITAL, LLC",401104260,MEDISCA INC,2020,first_quarter,PHA,"Guidance documents, compounding pharmacy, appropriations language.","Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2020-04-15T16:18:41.893000-04:00
2426933,1f0cf912-97fa-439a-b132-5e2df1926af5,1T,"POLITICAL CAPITAL, LLC",401104260,PINE PHARMACEUTICALS,2020,first_quarter,PHA,"Guidance documents, compounding pharmacy, appropriations language.","Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2020-04-15T16:22:43.757000-04:00
2426954,080dfbbd-e9c3-4a39-93bf-6be68da8ade0,Q1,"POLITICAL CAPITAL, LLC",401104260,STOKES PHARMACY,2020,first_quarter,PHA,Compounding,"Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-15T16:26:48.770000-04:00
2427075,7ffacda4-c283-4b91-ab36-b86c1112a0cd,Q1,BROYDRICK & ASSOCIATES,7268,EXELA PHARMA SCIENCES,2020,first_quarter,PHA,Drug shortages and FDA approval. USTR acceptance.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-15T17:25:25.787000-04:00
2427124,a7dfd8b6-1456-46b4-afee-1b34a87be33b,Q1,BROYDRICK & ASSOCIATES,7268,TONIX PHARMACEUTICALS,2020,first_quarter,PHA,Funding new drug for PTSD.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-15T17:44:42.340000-04:00
2427194,d2803cfd-d9c6-4f3d-aea6-a595c4703675,Q1,"MEHLMAN CONSULTING, INC.",284950,AMERICA'S HEALTH INSURANCE PLANS,2020,first_quarter,PHA,Prescription drug pricing,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",90000,,0,0,2020-04-15T21:10:06.653000-04:00
2427204,d7ad3d1e-3a04-45b4-b626-f027a25c2bba,Q1,"MEHLMAN CONSULTING, INC.",284950,ASCENSION HEALTH ALLIANCE,2020,first_quarter,PHA,"340B Drug Pricing Program. 
S.1895 - Lower Health Care Costs Act
H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123
H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136
Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-15T21:37:08.847000-04:00
2427208,005221bd-0642-4a66-b0f5-42ff6b48d430,Q1,"MEHLMAN CONSULTING, INC.",284950,ASSOCIATION OF ACCESSIBLE MEDICINES,2020,first_quarter,PHA,"Medicaid and Medicare drug pricing.
Prescription drug pricing.
H.R. 965 - CREATES Act of 2019.
H.R. 985 -  FAST Generics Act of 2019.
S.1895 - Lower Health Care Costs Act.
S. 440 - PACED Act
H.R. 938 - BLOCKING Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-15T21:40:09.347000-04:00
2427221,fb2ed54a-7c8d-470b-a570-2768031afe58,Q1,"MEHLMAN CONSULTING, INC.",284950,BLUE SHIELD OF CALIFORNIA,2020,first_quarter,PHA,"Prescription drug pricing.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-15T21:58:12.890000-04:00
2427360,a75529e2-7f7e-4e30-858d-f3096ba335aa,Q1,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,26672,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2020,first_quarter,PHA,"H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act

S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act

S.340 CREATES Act of 2019

H.R. 985 FAST Generics Act of 2019

S.640 Phair Pricing Act of 2019

S. 97 Affordable and Safe Prescription Drug Importation Act 

S. 61 Safe and Affordable Drugs from Canada Act of 2019

H.R. 1034 Phair Pricing Act of 2019

H.R. 965 CREATES Act of 2019

H.R. 1478 Affordable Insulin Act of 2019

H.R. 447 Affordable and Safe Prescription Drug Importation Act 

H.R. 1499 Protecting Consumer Access to Generic Drugs Act

H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019

H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019

H.R. 1607 Fairness to Pet Owners Act

H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act

H.R. 478 Safe and Affordable Drugs from Canada Act of 2019

H.R. 3 Lower Drug Costs Now Act of 2019

H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019

H.R. 448 Medicare Drug Price Negotiation Act

H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019

H.R. 5304 PBM Transparency in Prescription Drug Costs Act

H.R. 5172 NOPAIN Act

S. 2543 Prescription Drug Pricing Reduction Act of 2019

S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019

S. 2247 Phair Relief Act of 2019

S. 3070 Preventing Pill Mills Through Data Sharing Act

H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019

H.R. 19 Lower Costs, More Cures Act on 2019

S. 3129 Lower Costs, More Cures Act on 2019

H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act","HOUSE OF REPRESENTATIVES,SENATE",,460000,0,0,2020-04-16T08:52:53.837000-04:00
2427362,03710cad-aa75-4e6f-902f-2a60447a9b7b,Q1,MR. VINCENT A. PANVINI,401008845,PHRMA,2020,first_quarter,PHA,Position on Price Controls; Intellectual Property Rights; Illegal Importation of Biopharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-16T08:56:55.847000-04:00
2427367,de0a74a0-d136-4aea-9f57-4e32ac274798,Q1,MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP),24486,AMAZON.COM,2020,first_quarter,PHA,Drug pricing & transparency,"Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT)",60000,,0,0,2020-04-16T08:56:57.080000-04:00
2427421,0ad11802-0b52-4cdf-b702-b2ed24f79302,Q1,MCDERMOTT+ LLC,401103287,CAMPAIGN FOR SUSTAINABLE DRUG PRICING,2020,first_quarter,PHA,"S. 1895 - Lower Health Care Costs Act
H.R. 985 - FAST Generics Act of 2019
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-16T09:25:07.767000-04:00
2427456,e392d317-a9ad-42e6-bc06-949740706704,Q1,THE MATHIS HARPLE GROUP,322911,PILMA,2020,first_quarter,PHA,"HR 3, Price Controls, Intellectual Property Rights, Patent Protections","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-16T09:38:16.307000-04:00
2427483,80ddeddc-2961-4dc5-9c86-75490e4efdbf,1T,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2020,first_quarter,PHA,Issues related to the 340B drug discount program and drug pricing policies,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,1,2020-04-16T09:46:24.477000-04:00
2427501,7e0fd076-e271-4082-b3e5-da2626da6471,1T,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2020,first_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,1,2020-04-16T09:50:28.300000-04:00
2427528,827811d9-41a5-4d80-b3cc-c4bd38949810,1T,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2020,first_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,1,2020-04-16T09:56:37.020000-04:00
2427969,df9326a4-fd23-4469-a766-2b44f661db67,Q1,THE MATHIS HARPLE GROUP,322911,PHRMA,2020,first_quarter,PHA,"Price Controls, Intellectual Property Rights, Patent Protections, HR3","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T11:43:41.293000-04:00
2428013,4cf73ccf-fcab-4f34-810c-ded7c53ad4aa,Q1,"OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC",30212,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2020,first_quarter,PHA,"Drug pricing, Direct and Indirect remuneration fees, Medicare, COVID-19","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2020-04-16T11:52:59.257000-04:00
2428500,3748ab5e-997d-4176-93f8-3f6dda809949,Q1,"MEHLMAN CONSULTING, INC.",284950,FOOD ALLERGY RESEARCH & EDUCATION (FARE),2020,first_quarter,PHA,Labeling of allergens.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-16T13:13:50.327000-04:00
2428775,32e45db2-da71-4a4f-92bf-596136eb1434,Q1,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2020,first_quarter,PHA,"Opioid and prescription drug pricing issues; Rx drug rebates; regulation of pharmacy benefit managers; CREATES Act;.

H.R.3 - 116th Congress (2019-2020)
Lower Drug Costs Now Act of 2019","HOUSE OF REPRESENTATIVES,SENATE",,15000,0,0,2020-04-16T14:07:22.337000-04:00
2428989,55e71d74-a2a7-456c-881c-ab91a634af22,Q1,"BROWN & FORTUNATO, P.C.",401104878,"PROMPTCARE COMPANIES, INC.",2020,first_quarter,PHA,"Issues related to Medicare home infusion therapy benefit and other health care issues.  Issues related to the Medicare DMEPOS competitive bidding program.  Issues related to H.R. 4945 - Safeguarding Medicare Access to Respiratory Therapy Act of 2019; H.R. 1865 - Further Consolidated Appropriations Act, 2020; H.R. 748 - CARES Act; H.R. 6201 - Family First Coronavirus Response Act.  Issues related to H.R. 6218 and S. 3457 - The Preserving Medicare Access to Home Infusion Act.",Centers For Medicare and Medicaid Services (CMS),20000,,0,0,2020-04-16T14:57:24.613000-04:00
2429137,398c6237-536b-45d0-83ca-b14fff0aaefe,Q1,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2020,first_quarter,PHA,"Prescription Drugs

H.R. 3 - The Lower Drug Costs Now Act","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2020-04-16T15:38:08.410000-04:00
2429313,0dad3a65-2c9c-4a1d-a62b-20b53fc1ccf8,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,"GLENMARK PHARMACEUTICALS, INC., USA",2020,first_quarter,PHA,"General information about the company and the industry.  Issues related to affordability and pricing of pharmaceuticals.  Issues related to H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including drug supply chain dynamics.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-16T16:34:00.480000-04:00
2429863,3604a3bd-c709-42b4-9c4b-eccf080aff2d,Q1,VAN SCOYOC ASSOCIATES,39837,ZEBRA TECHNOLOGIES CORP.,2020,first_quarter,PHA,"Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation 

Temperature monitoring technology for vaccines",HOUSE OF REPRESENTATIVES,30000,,0,0,2020-04-17T05:28:38.750000-04:00
2430057,43d50a51-cb21-459a-9c03-21525d726a33,Q1,AARP,1694,AARP,2020,first_quarter,PHA,"H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act. 

H.R. 6201, Families First Coronavirus Response Act; H.R. 748, Coronavirus Aid, Relief, and Economic Security  (CARES) Act - Discussed Medicare enrollment national open enrollment period, medical expense deduction, cost-sharing protections for commercial/private health insurance holders, telehealth access, nursing homes, virtual visitation, home and community-based services, Older Americans Act programs, Medicare home health care, and family caregiving, no-cost COVID-19 testing, equitable relief payments, retirement savings tax relief, suspensions of foreclosures and evictions, expanded unemployment benefits, paid sick and family leave, affordable broadband, and government operations, among other issues.

H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act.

S. 2543, the Prescription Drug Pricing Reduction Act.

S.64/H.R. 2375 - the Preserve Access to Generics and Biosimilars Act.

H.R. 1499 - the Preserving Consumer Access to Generics Act.

H.R. 2113 - the Prescription STAR Act.

H.R. 2296/S.1391 - The FAIR Drug Pricing Act.

S.1416 - the Affordable Prescriptions for Patients Act.

S.1437, the Drug-price Transparency in Communications (DTC) Act.

S.551, the REFUND Act.

S.1209, the REMEDY Act.

S. 474/H.R. 2069, the SPIKE Act.

H.R. 19/S. 3129, Lower Cost More Cures Act.","Administration for Children & Families (ACF),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Federal Deposit Insurance Corporation (FDIC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Indian Health Service,Internal Revenue Service (IRS),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of the Comptroller of the Currency (OCC),Pension Benefit Guaranty Corporation (PBGC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office",,2210000,0,0,2020-04-17T07:49:26.393000-04:00
2430212,42c0770f-f682-46e4-ac49-5c31309fb8d5,1A,"RUBICON ADVISORS, LLC",315091,AVET PHARMACEUTICALS,2020,first_quarter,PHA,"GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM AND COVID-19 FDA DRUG SHORTAGES",HOUSE OF REPRESENTATIVES,30000,,0,0,2020-04-17T09:00:40.367000-04:00
2430260,056ef3b1-9219-4e18-89ae-18f3c627f9d3,Q1,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2020,first_quarter,PHA,Hospital discounts; 340B program,"Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,1290000,0,0,2020-04-17T09:31:10.340000-04:00
2430370,59a283e4-f8f1-44a3-a799-02c2caa78fe9,Q1,LINCOLN PARK GROUP L.L.C.,401104374,CANADIAN INTERNATIONAL PHARMACY ASSOCIATION,2020,first_quarter,PHA,Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-04-17T10:02:32.733000-04:00
2430448,0ee28ee8-c53c-452d-ac4c-0da415b736c9,Q1,WINNING STRATEGIES WASHINGTON,50796,KALEO,2020,first_quarter,PHA,"Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues","Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-04-17T10:16:53.520000-04:00
2430480,92344024-7f13-47b5-95cb-dbfb0850ab00,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2020,first_quarter,PHA,N/A,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE",,70000,0,0,2020-04-17T10:23:06.180000-04:00
2430631,93a86536-68be-4b39-98d8-17b50cafbd14,Q1,"FLYNN & ASSOCIATES, INC.",15020,PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION,2020,first_quarter,PHA,"H.R. 3 Lower Drug Prices- Cummings Act
Drug importation from Canada","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-17T10:40:30.880000-04:00
2430661,fc01841f-aa2d-4cde-9384-d67629fbf0e8,Q1,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2020,first_quarter,PHA,"H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019;
H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019;
H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019;
H.R. 5198, the Patients' Right to Know Their Medication Act of 2019;
H.R. 5304, the PBM Transparency in Prescription Drug Costs Act","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office",,440000,0,0,2020-04-17T10:44:36.663000-04:00
2431266,55406673-87ff-46c3-8ee3-fcda40235c3b,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2020,first_quarter,PHA,"Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019.  Changes to the Risk Evaluation and Mitigation Strategies (REMS) program.  Reimbursement rate for biosimilars.  S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3,The Lower Drug Costs Now Act. H. R. 1865. Issues related to H. R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including supply chain issues for generic medicines.","Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),White House Office",60000,,0,0,2020-04-17T11:56:52.660000-04:00
2431377,763954e0-17b9-456a-accb-b5ff89078a22,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2020,first_quarter,PHA,"Issues related to drug pricing in the pharmaceutical supply chain.  Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to H.R.748, Coronavirus Aid,Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-17T12:12:18.907000-04:00
2431390,88f2e40b-fbc4-4677-b20c-b21bd92b780a,Q1,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2020,first_quarter,PHA,"Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)
Issues related to ARCOS data and suspicious order record requirements and reporting (S. 3070, S. 2686, HR 4814)
Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) 
Implementation of Public Law 113-54 (DSCSA) 
Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) 
Preventing Pill Mills Through Data Sharing Act - S. 3070
Suspicious Order Identification Act of 2019 - S. 2686
Suspicious Order Identification Act of 2019 - HR 4814","Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,313210,0,0,2020-04-17T12:13:22.103000-04:00
2431437,5d0404cf-b507-4bdd-9886-f83aa6d2fc87,Q1,"BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.",323876,BLUE CROSS AND BLUE SHIELD OF KANSAS INC,2020,first_quarter,PHA,"Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Rx Rebates; Biosimilars; Drug approval; Drug patents, generic drugs, Part D Reform; Civica Rx

H.R.1499 - 116th Congress (2019-2020)
Protecting Consumer Access to Generic Drugs Act of 2019
Sponsor: Rep. Rush, Bobby [D-IL-1](Introduced 03/08/2019)

H.R.965 - 116th Congress (2019-2020)
CREATES Act of 2019
Sponsor: Rep. Cicilline, David [D-RI-1](Introduced 02/05/2019)

H.R.3 - 116th Congress (2019-2020)
Lower Drug Costs Now Act of 2019
Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6](Introduced 09/19/2019)

H.R.275 - 116th Congress (2019-2020)
Medicare Prescription Drug Price Negotiation Action of 2019
Sponsor: Rep. Welch, Peter [D-VT-At Large](Introduced 01/08/2019)

H.R.448 - 116th Congress (2019-2020)
Medicare Drug Price Negotiation Act
Sponsor: Rep. Cummings, Elijah E. [D-MD-7](Introduced 01/10/2019)

H.R.1046 - 116th Congress (2019-2020)
Medicare Negotiation and Competitive Licensing Act of 2019
Sponsor: Rep. Doggett, Lloyd [D-TX-35](Introduced 02/07/2019)

S.3092 - 116th Congress (2019-2020)
Expanding Access to Low-Cost Generics Act of 2019
Sponsor: Sen. Smith, Tina [D-MN](Introduced 12/18/2019)

H.R.19 - 116th Congress (2019-2020)
Lower Costs, More Cures Act of 2019
Sponsor: Rep. Walden, Gred [R-OR-2](Introduced 12/09/2019)

H.R.6193 - 116th Congress (2019-2020)
Medication Access in Emergencies Act of 2020
Sponsor: Rep Pappas, Chris [D-NH-1](Introduced 03/11/2020)

H.R.5578 - 116th Congress (2019-2020)
Recall Unsafe Drugs Act of 2020
Sponsor: Rep. Delauro, Rosa [D-CT-3](Introduced 01/10/2020)

H.R.5691 - 116th Congress (2019-2020)
Insulin Affordability Data Collection Act
Sponsor: Rep. Craig, Angie [D-MN-2](Introduced 01/28/2020)

H.R.5894 - 116th Congress (2019-2020)
Transparency in Prescription Drug Advertising Act
Sponsor: Rep Davids, Sharice [D-KS-3](Introduced 02/13/2020)","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-17T12:18:35.750000-04:00
2431560,322c13ec-542e-4554-b20d-66c9b0d30f31,Q1,KAISER FOUNDATION HEALTH PLAN INC.,21027,KAISER FOUNDATION HEALTH PLAN INC,2020,first_quarter,PHA,"S. 3129, Crapo The Lower Costs, More Cures Act
HR 19 Walden, the Lower Costs, More Cures Act
HR 5444 Underwood, Lower Insulin Costs Now Act
S. 3052, Grassley, the US, Mexico and Canada Trade Agreement Implementation Act
HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act
HR 4906, DeGette, Regarding the costs of insulin
HR 5442, Porter, regarding drug pricing
S. 2543, Prescription Drug Pricing Reduction Act
HR 2296, regarding prescription drug pricing
HR 3, regarding prescription drug pricing (Pelosi)
HR 4455, regarding Biologics in Medicare Part  D
HR 4378, Continuing Appropriations and Health Extenders Act
S. 2543, Prescription Drug Pricing Reduction Act
HR 1781, regarding access to data for MedPAC and MACPAC
HR 2113, regarding drug price transparency
HR 2374, regarding generic drugs and citizens petitions
HR 2375, regarding pay for delay agreements and generic drugs
HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain
HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers
HR 478 and S. 61, regarding drug reimportation
HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act)
HR 1499, regarding pay for delay in pharmaceutical markets
HR 1503, regarding the FDA Orange Book
HR 1520, regarding the FDA Purple Book
HR 938, regarding generic drug approvals
HR 2113, regarding drug pricing transparency","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,670000,0,0,2020-04-17T12:33:12.550000-04:00
2431640,4f08bc88-aa7b-49f3-9ac2-4f356075c86e,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2020,first_quarter,PHA,"Issues related to the 340B Drug Pricing Program, biomedical research and Medicare, COVID-19/Coronavirus Response Legislative Initiatives","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-17T12:41:30.817000-04:00
2431789,4f1da57a-bb66-4faa-9828-597be39adf0a,Q1,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,400271247,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2020,first_quarter,PHA,Issues associated with proposed changes to the 340B Discount Drug Program,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Patent & Trademark Office (PTO),SENATE",,25000,0,0,2020-04-17T13:12:15.377000-04:00
2431907,0af66202-d6b7-44f3-8222-f6533ead8c19,Q1,BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC,401104621,BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC,2020,first_quarter,PHA,"HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies","HOUSE OF REPRESENTATIVES,SENATE",,100000,0,0,2020-04-17T13:26:33.017000-04:00
2431940,5213a711-2fb8-4a5c-b217-c4292e5368af,Q1,E3 STRATEGIC CONSULTING GROUP,401104104,HEINZ STRATEGIES LLC (ON BEHALF OF PILMA),2020,first_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-17T13:29:41.237000-04:00
2431948,a6d85cca-19cc-43a9-9212-ca335d1d53ad,Q1,E3 STRATEGIC CONSULTING GROUP,401104104,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2020,first_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-17T13:30:42.320000-04:00
2431954,9a287153-3999-4436-8556-6560687e0b2f,Q1,"PARK STREET STRATEGIES, LLC",401103554,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2020,first_quarter,PHA,Monitor legislation to change 340B Discount Drug Program,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Patent & Trademark Office (PTO),SENATE",5000,,0,0,2020-04-17T13:31:43.290000-04:00
2431988,081a86a7-e803-45d7-af4d-3932ee4c7bb8,Q1,HCM STRATEGISTS,400459263,ALLIANCE OF COMMUNITY HEALTH PLANS,2020,first_quarter,PHA,"2593, The Prescription Drug Pricing Reduction Act (PDPRA) of 2019
HR 3, The Elijah E. Cummings Lower Drug Costs Now Act",,,,0,0,2020-04-17T13:38:53.297000-04:00
2432257,6f30ba35-c63b-46c8-bb80-5096466c1335,Q1,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2020,first_quarter,PHA,"H.R. 789 - To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.
H.R. 803 - This bill prohibits Medicare prescription drug plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A ""clean claim"" is a Medicare claim that is free of defects such as incomplete documentation.)
H.R. 1034 - Phair Pricing Act of 2019; To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program
S. 640 - To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program, and for other purposes.
S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.
S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.
H.R. 3 Lower Drug Costs Now Act of 2019-To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
S.2543 Prescription Drug Pricing Reduction Act of 2019 -To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.
HR 5304 PBM Transparency in Prescription Drug Cost Act - 
To amend title XXVII of the Public Health Service Act to require health plan oversight of pharmacy benefit manager service
HR 5442 - Lowest Price for Patients Act - To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes.
S. 3129 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, and for other purposes.
HR 19 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes. Lower Costs, More Cures Act of 2019.
HR 3 -To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
HR 6021 - pharmacy and pharmacist provisions in emergency supplemental appropriations for the fiscal year ending September 30, 2020, and for other purposes due coronoavirus pandemic. 
hr 6074 - pharmacist and pharmacy provisions in bill to provide FY2020 supplemental appropriations for the Department of Health and Human Services (HHS), the State Department, and the Small Business Administration to respond to the coronavirus outbreak.
HR 748 - This bill responds to the COVID-19 (i.e., coronavirus disease 2019) outbreak and its impact on the economy, public health, state and local governments, individuals, and businesses.","HOUSE OF REPRESENTATIVES,SENATE",,34000,0,0,2020-04-17T14:15:11.293000-04:00
2432272,23d550f4-ab48-4062-a87a-927d069b1791,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2020,first_quarter,PHA,"General issues related to over the counter pharmaceuticals.  Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 3443/S2740, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-17T14:16:14.783000-04:00
2432367,cb74e90e-8742-46d7-9993-4d532bd37a51,Q1,"TWENTY-FIRST CENTURY GROUP, INC.",38687,"CARDINAL HEALTH, INC.",2020,first_quarter,PHA,Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response;and the healthcare supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-04-17T14:32:36.437000-04:00
2432385,0bfc5c42-e7dd-4c5c-8732-e16c144b3cd9,Q1,"ML STRATEGIES, LLC",25603,LEADING BIOSCIENCES,2020,first_quarter,PHA,Issues related to potential funding opportunities for Coronavirus (COVID-19),,10000,,0,0,2020-04-17T14:34:40.123000-04:00
2432393,59de80b6-139e-440e-a725-097d1fb869f7,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CVS HEALTH,2020,first_quarter,PHA,"General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act.  Issues related to Risk Evaluation and Mitigation Strategies (REMS) program.  S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.  Issues related to H.R.748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including provisions relating to the drug supply chain.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-17T14:36:41.257000-04:00
2432396,675b4014-4455-49fb-af89-dfea66b51b82,Q1,340B HEALTH,316434,340B HEALTH,2020,first_quarter,PHA,"The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 3, Lower Drug Costs Now Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 5281, Drug Price Transparency in Medicaid Act of 2019; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act; HR 19, Lower Costs, More Cures Act of 2019","Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",,363453,0,0,2020-04-17T14:36:42.497000-04:00
2432417,8aab637f-976d-44ec-a2dd-4cbf01b31f42,Q1,PANNONE LOPES DEVEREAUX & O'GARA LLC,401105501,AMGEN,2020,first_quarter,PHA,Prescription drug pricing.,HOUSE OF REPRESENTATIVES,,,0,0,2020-04-17T14:38:47.277000-04:00
2432609,66e763b4-b81e-464b-9146-8f6ea12abbcd,Q1,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2020,first_quarter,PHA,"Communication and correspondence on lowering health care costs, support to changes in 42 C.F.R., dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr) and issues related to coronavirus relief.","HOUSE OF REPRESENTATIVES,SENATE",,51875,0,0,2020-04-17T15:01:39.170000-04:00
2432624,5f8b09c3-f560-4a6c-9e98-d2b0a65987db,Q1,HANCE SCARBOROUGH,17443,ALLIANCE FOR PHARMACY COMPOUNDING,2020,first_quarter,PHA,"Issues related to the regulation of pharmacy compounding.  

HR 1959 Preserving Patient Access to Compounded Medications Act.

CARES Act H.R. 748","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-17T15:02:16.570000-04:00